Visual quality of life in NMOSD and MOGAD: profiles, dynamics and associations with ageing and vision

• Published in: Journal of neurology 2025, Vol.272 (1), p.86
• Main Authors: Nicolescu, Mihaela, Häußler, Vivien, Paul, Friedemann, Oertel, Frederike Cosima, Schindler, Patrick, Strobl, Judith Bellmann, Krumbholz, Markus, Hümmert, Martin W., Bütow, Franziska, Tkachenko, Daria, Trebst, Corinna, Schubert, Charlotte, Ayzenberg, Ilya, Schwake, Carolin, Pakeerathan, Thivya, Fischer, Katinka, Aktas, Orhan, Ringelstein, Marius, Kraemer, Markus, Warnke, Clemens, Grothe, Matthias, Kaste, Matthias, Angstwurm, Klemens, Kern, Peter, Kleiter, Ingo, Rommer, Paulus, Winkelmann, Alexander, Walter, Annette, Weber, Martin S., Wickel, Jonathan, Giglhuber, Katrin, Then Bergh, Florian, Senel, Makbule, Tumani, Hayrettin, Vardakas, Ioannis, Dawin, Eva, Revie, Lisa, Klotz, Luisa, Korporal-Kuhnke, Mirjam, Jarius, Sven, Wildemann, Brigitte, Gernert, Jonathan A., Kümpfel, Tania, Engels, Daniel, Havla, Joachim, Stolowy, Natacha, Stellmann, Jan-Patrick
• Format: Article
• Language: English
• Subjects: Acuity; Age differences; Aging; Medicine; Medicine & Public Health; Multiple sclerosis; Myelin; Neurological complications; Neurology; Neuromyelitis; Neuroradiology; Neurosciences; Oligodendrocyte-myelin glycoprotein; Original Communication; Quality of life; Social behavior; Vision; Visual acuity; Visual evoked potentials; Visual perception
• ISSN: 0340-5354; 1432-1459; 1432-1459
• DOI: 10.1007/s00415-024-12803-5

Objective In this multicentric study, we were interested in the vision-related quality of life and its association with visual impairment in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in comparison to multiple sclerosis (MS) and healthy controls. Methods We analysed extracted data from the German NEMOS registry including National Eye Institute Visual Function Questionnaire (NEI-VFQ) scores, high and low contrast visual acuity (HCVA, LCVA), visually evoked potentials (VEP) and the scores for the expanded disability status scale (EDSS) and other neurological tests which assessed their disease-related impairment. The mean follow-up time of our patients was 1.2 years. We used adjusted linear mixed effect models to analyse NEI-VFQ differences and interactions with visual acuity among NMOSD, MOGAD, a matched MS cohort and healthy controls. Results Despite a younger age in the MOGAD cohort (39 y.o.), vision and socioemotional-related quality of life reduction was similar over all patient subgroups in comparison to healthy controls. The most impacted life quality dimension was general health, followed by general vision, driving and role difficulties. Decline in some of the NEI-VFQ subscales scores is mostly predicted by age. The HCVA was the best predictor for most of the subscales of the NEI-VFQ. Discussion Despite important age differences, NMOSD, MOGAD and MS seem to share a rather similar perception on their vision and quality of life impairment, which is overall poorer than that of healthy controls.